文献速递骨质疏松与钙磷/甲状旁腺垂体与肾上腺疾病

大型成骨不全/骨质疏松症患者队列中WNT1变异的基因型与表型谱及发病机制

Genotypic and Phenotypic Spectrum and Pathogenesis of WNT1 Variants in a Large Cohort of Patients With OI/Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该研究纳入16例携带16种WNT1突变的成骨不全或早发性骨质疏松症患者,评估其表型、基因型及对双膦酸盐或地舒单抗的治疗反应。双等位基因无义突变或移码突变可导致脆性骨折更早发生和骨骼表型更严重。双膦酸盐和地舒单抗显著提高脊柱和髋部近端骨密度并重塑压缩椎体。

要点

  • 双等位基因无义或移码突变与更早脆性骨折和更严重骨骼表型相关。
  • 双膦酸盐和地舒单抗显著提高WNT1突变患者脊柱和髋部近端骨密度。
  • 首次报告患者骨组织β-连环蛋白水平较健康对照降低。

核心结论

  • WNT1双等位基因无义突变或移码突变可导致成骨不全和早发性骨质疏松症患者脆性骨折更早发生及骨骼表型更严重。
  • WNT通路下调所致成骨活性降低可能是WNT1相关成骨不全和早发性骨质疏松症的潜在致病机制。

研究设计与样本

  • 研究纳入16例携带16种WNT1突变的患者,评估其表型、基因型及对双膦酸盐或地舒单抗的治疗反应。
  • 采用蛋白质印迹、定量聚合酶链反应和免疫荧光染色检测一名患者胫骨或皮肤中WNT1、总β-连环蛋白和I型胶原表达水平。

主要发现

  • WNT1突变类型与骨骼表型相关,双等位基因无义突变或移码突变可导致脆性骨折更早发生和骨骼表型更严重。
  • 该队列发现罕见合并症包括脑部异常、血液系统疾病和垂体腺瘤。
  • 双膦酸盐和地舒单抗显著提高WNT1突变患者脊柱和髋部近端骨密度,并重塑压缩椎体。
  • 首次报告患者10(携带c.677C > T和c.502G > A)骨组织β-连环蛋白水平较健康对照降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Mutations in WNT1 can cause rare inherited disorders such as osteogenesis imperfecta (OI) and early-onset osteoporosis (EOOP). Owing to its rarity, the clinical characteristics and pathogenic mechanism of WNT1 mutations remain unclear. OBJECTIVE: We aimed to explore the phenotypic and genotypic spectrum and treatment responses of a large cohort of patients with WNT1-related OI/OP and the molecular mechanisms of WNT1 variants. METHODS: The phenotypes and genotypes of patients and their responses to bisphosphonates or denosumab were evaluated. Western blot analysis, quantitative polymerase chain reaction, and immunofluorescence staining were used to evaluate the expression levels of WNT1, total β-catenin, and type I collagen in the tibial bone or skin from one patient. RESULTS: We included 16 patients with 16 mutations identified in WNT1, including a novel mutation. The types of WNT1 mutations were related to skeletal phenotypes, and biallelic nonsense mutations or frameshift mutations could lead to an earlier occurrence of fragility fractures and more severe skeletal phenotypes. Some rare comorbidities were identified in this cohort, including cerebral abnormalities, hematologic diseases, and pituitary adenoma. Bisphosphonates and denosumab significantly increased the spine and proximal hip BMD of patients with WNT1 mutations and reshaped the compressed vertebrae. We report for the first time a decreased β-catenin level in the bone of patient 10 with c.677C > T and c.502G > A compared to the healthy control, which revealed the potential mechanisms of WNT1-induced skeletal phenotypes. CONCLUSION: Biallelic nonsense mutations or frameshift mutations of WNT1 could lead to an earlier occurrence of fragility fractures and a more severe skeletal phenotype in OI and EOOP induced by WNT1 mutations. The reduced osteogenic activity caused by WNT pathway downregulation could be a potential pathogenic mechanism of WNT1-related OI and EOOP.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hu J, Lin X, Gao P, et al. Genotypic and Phenotypic Spectrum and Pathogenesis of WNT1 Variants in a Large Cohort of Patients With OI/Osteoporosis. J Clin Endocrinol Metab. 2023. PMID: 36595228. doi:10.1210/clinem/dgac752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。